Hepcidin Agents Set to Improve Polycythemia Vera Care Protagonist Therapeutics earlier this month reported positive results from its phase III VERIFY study of hepcidin mimetic rusfertide for th...

#Hepcidin agents set to improve #PolycythemiaVera care (blog): rnaitherapeutics.blogspot.com/2025/03/hepc...

$PTGX $SLN $IONS #rusfertide #divesiran #sapablursen

#PolycythemiaVera following $PTGX rusfertide p3 data release, $IONS finalizes global licensing deal with phase 2 TMPRSS6 ASO kd agent #sapablursen with Ono.

$280M upfront, i.e. more than $210M market cap of $SLN which has rival RNAi TMPRSS6 kd agent.

ir.ionis.com/news-release...